Daniela Spitzer, MD
Internal Medicine · Yorktown Heights, NYNPI 1184738510
Payments from drug & device makers
Across 313 payments — averaging $17.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Boehringer Ingelheim$504
- Novo Nordisk$454
- Cumberland Pharmaceuticals, Inc.$347
- Amarin Pharma, Inc.$326
- Lilly USA, LLC$289
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,39299%
- Education$691%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 80 | $1,226 |
| Boehringer Ingelheim | 20 | $504 |
| Novo Nordisk | 24 | $454 |
| Cumberland Pharmaceuticals, Inc. | 23 | $347 |
| Amarin Pharma, Inc. | 21 | $326 |
| Lilly USA, LLC | 22 | $289 |
| Merck | 14 | $200 |
| AstraZeneca | 13 | $185 |
| Amneal Pharmaceuticals LLC | 13 | $180 |
| Pfizer | 11 | $178 |
| Heartflow, Inc. | 1 | $155 |
| Novartis | 10 | $151 |
| Medtronic | 1 | $143 |
| Optinose US, Inc. | 7 | $120 |
| Bayer | 1 | $115 |
| GSK | 6 | $109 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $103 |
| Johnson & Johnson | 5 | $99 |
| Kowa Pharmaceuticals America, Inc. | 6 | $95 |
| Sanofi-aventis U.S. LLC | 5 | $83 |
| Eisai Inc. | 4 | $67 |
| Abbott | 4 | $54 |
| Arbor Pharmaceuticals, Inc. | 3 | $40 |
| Genentech USA, Inc. | 3 | $40 |
| Astellas Pharma US Inc | 2 | $33 |
| Currax Pharmaceuticals LLC | 2 | $27 |
| Daiichi Sankyo Inc. | 2 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $21 |
| Ironwood Pharmaceuticals, Inc | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $12 |
| IBSA Pharma Inc. | 1 | $12 |
| Biohaven Pharmaceuticals, Inc. | 1 | $11 |
| Esperion Therapeutics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FFRct$155
- O-ARM$143
- Wegovy$125
- Kerendia$115
- NURTEC ODT$103
How this compares
$5,461 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 70 | $99,594 |
| EliquisApixaban | 46 | $42,087 |
| JanuviaSitagliptin Phosphate | 25 | $38,190 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $22,128 |
| ProliaDenosumab | 13 | $21,995 |
| OzempicSemaglutide | 24 | $20,911 |
| MounjaroTirzepatide | 12 | $15,991 |
| VascepaIcosapent Ethyl | 20 | $13,391 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 191 | $6,046 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $5,854 |
| Atorvastatin Calcium | 543 | $5,364 |
| Rosuvastatin Calcium | 290 | $4,155 |
| LivaloPitavastatin Calcium | 11 | $3,657 |
| Levothyroxine Sodium | 261 | $3,595 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $3,400 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $504 | $99,59470 claims |
| PfizerEliquis, Dilantin | $178 | $43,37058 claims |
| MerckJanuvia | $200 | $38,19025 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $109 | $27,98239 claims |
| Novo NordiskOzempic | $454 | $20,91124 claims |
| Lilly USA, LLCMounjaro | $289 | $15,99112 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $95 | $3,65711 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $180 | $3,595261 claims |
| AbbVieSynthroid | $1,226 | $2,99952 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Yorktown Heights
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.